Key Takeaways:
Neurocrine Biosciences Inc. will acquire Soleno Therapeutics Inc. for $2.9 billion in cash, a deal that adds a newly approved, first-in-class treatment for a rare genetic disorder to its portfolio.
The acquisition, announced by the companies on April 6, 2026, is structured for Neurocrine to acquire all outstanding shares of Soleno for $53.00 per share in cash. The move significantly expands Neurocrine's presence in endocrinology and rare diseases.
The transaction centers on Soleno's lead asset, VYKAT™ XR (diazoxide choline), the first and only treatment approved by the US Food and Drug Administration for hyperphagia, or chronic excessive hunger, in patients with Prader-Willi syndrome. The addition of VYKAT XR gives Neurocrine a third major commercial drug, joining its existing blockbuster INGREZZA® (valbenazine) and the recently approved CRENESSITY® (crinecerfont).
For Soleno, the $53.00 per share cash offer provides a substantial premium, while Neurocrine projects the deal will create long-term value, supported by a strong intellectual property estate for VYKAT XR expected to last into the mid-2040s. The acquisition is expected to be a key driver of durable revenue growth for Neurocrine.
The deal strengthens Neurocrine's position as a leader in treating rare neurological and endocrine disorders. For investors, the focus will now shift to the successful closing and integration of Soleno, with the VYKAT XR launch being a critical upcoming catalyst.
This article is for informational purposes only and does not constitute investment advice.
